Equity · Healthcare
NKTR
NASDAQNektar Therapeutics (NKTR)
The line runs $76 on 7 August through $36 on 16 October, on a scale from $20 to $80. Days the market did not trade hold the previous close, flat.
- Market cap
- $1.2B
- 52-week range
- $35 – $98
- Avg volume
- 75.7K
as of Oct 16, 2026
Have Nektar Therapeutics (NKTR) insiders bought or sold shares recently?
In the 90 days to 28 Oct 2026, Nektar Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 30 Sep 2025, show no open-market purchase.
Form 4, 90 days to 28 Oct 2026, newest reported trade 18 Aug 2026
Buys 0Sells 2Net sold $43KOther filings 5
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 Aug 2026 | Zalevsky JonathanChief R&D Officer | Sell | 186 | $13K |
| 18 Aug 2026 | ROBIN HOWARD WPresident & CEO | Sell | 418 | $30K |
| Sold | 2 open-market sales | 604 | $43K |
5 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 23 Sep 2026 | WHITFIELD ROY ADirector | Award | 2,000 | |
| 23 Sep 2026 | GREER R SCOTTDirector | Award | 2,000 | |
| 23 Sep 2026 | CHESS ROBERTDirector | Award | 2,000 | |
| 23 Sep 2026 | Brainard DianaDirector | Award | 2,000 | |
| 23 Sep 2026 | Ajer Jeffrey RobertDirector | Award | 2,000 |
Which funds hold Nektar Therapeutics (NKTR)?
5 of the 45 institutional funds we track reported a Nektar Therapeutics position for the quarter ended 30 Jun 2026 — a combined $130.2M; the latest of those filings landed 02 Sep 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Added | 1,202,004 | $83.9M | +29.1% |
| Millennium Management | Held (±25%) | 478,120 | $33.4M | +18.3% |
| Citadel Advisors | Trimmed | 159,747 | $11.2M | −68.9% |
| AQR Capital Management | New position | 22,542 | $1.6M | |
| Marshall Wace | Trimmed | 3,300 | $230K | −97.7% |
| Balyasny Asset Management | Exited | |||
| Man Group | Exited | |||
| Point72 Asset Management | Exited | |||
| Renaissance Technologies | Exited | |||
| Tudor Investment Corp | Exited |
Have members of Congress traded Nektar Therapeutics (NKTR)?
The most recent congressional trade disclosed in Nektar Therapeutics is a purchase by Josh Gottheimer (house, NJ), dated 06 Jun 2018.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 06 Jun 2018 | Josh Gottheimerhouse · Democrat–NJ | Purchase | $1K–$15K | 118 days |
What has been filed or recorded for Nektar Therapeutics (NKTR)?
The filings we hold for Nektar Therapeutics, newest first: 5 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 30 Sep 2026 | Fails to deliver | Shares failed to deliver | 423 shares | $25K notional · 0.001% of shares out |
| 29 Sep 2026 | Fails to deliver | Shares failed to deliver | 7,035 shares | $425K notional · 0.021% of shares out |
| 22 Sep 2026 | Fails to deliver | Shares failed to deliver | 147,691 shares | $9.9M notional · 0.433% of shares out |
| 21 Sep 2026 | Fails to deliver | Shares failed to deliver | 165,383 shares | $11.1M notional · 0.484% of shares out |
| 17 Sep 2026 | Fails to deliver | Shares failed to deliver | 12,437 shares | $838K notional · 0.036% of shares out |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −$1.23 | |
| 30 Jun 2026 | Financials | Total assets | $1.1B | at period end |
| 30 Jun 2026 | Financials | Total equity | $903.1M | at period end |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −$1.82 | |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −$9.73 | |
| 31 Dec 2025 | Financials | Revenue | $55.2M | fiscal year |
| 31 Dec 2025 | Financials | Net income | −$164.1M | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −$9.73 | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −$1.87 | |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −$2.95 | |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −$3.62 | |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −$8.68 | |
| 30 Sep 2024 | Quarterly earnings | Q3 2024 reported | EPS −$2.66 |
Nektar Therapeutics (NKTR): frequently asked questions
What did Nektar Therapeutics shares close at?
Nektar Therapeutics closed at $36.00 on 16 Oct 2026, down 4.53% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Nektar Therapeutics’ market cap?
Nektar Therapeutics is worth $1.2B by market value as of 16 Oct 2026, which is the share price times the shares on issue from its SEC filings.
What is Nektar Therapeutics’ revenue?
Nektar Therapeutics reported revenue of $55.2M for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Nektar Therapeutics insiders bought or sold shares recently?
In the 90 days to 28 Oct 2026, Nektar Therapeutics insiders reported 2 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 30 Sep 2025, show no open-market purchase. A further 5 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Nektar Therapeutics?
5 of the 45 funds we track reported a Nektar Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Millennium Management and Citadel Advisors. See Funds
Have members of Congress traded Nektar Therapeutics?
Yes. 1 trade in Nektar Therapeutics appears in the congressional disclosures we hold: a purchase by Josh Gottheimer (House, NJ) dated 6 Jun 2018, filed 2 Oct 2018. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
When did Nektar Therapeutics last report earnings?
Nektar Therapeutics last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −$1.23; no next date is announced in SEC filings yet. See Filings
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings